Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
905 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01390948 | A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma | completed | Phase 2 | 124 | Hoffmann-La RocheINDUSTRY | 14 | Aug 6, 2020 | clinicaltrials |
| NCT01526928 | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | terminated | Phase 1 / Phase 2 | 612 | Clovis Oncology, Inc.INDUSTRY | 4 |
| Aug 4, 2020 |
| clinicaltrials |
| NCT01788982 | Nintedanib(BIBF1120) in Thyroid Cancer | completed | Phase 2 | 100 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 31, 2020 | clinicaltrials |
| NCT03669965 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | active not recruiting | Phase 2 | 20 | Kartos Therapeutics, Inc.INDUSTRY | 6 | Jul 31, 2020 | clinicaltrials |
| NCT00866970 | Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia | completed | Phase 2 | 124 | CSL BehringINDUSTRY | 9 | Jul 9, 2020 | clinicaltrials |
| NCT02443883 | A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer | completed | Phase 2 | 164 | Eli Lilly and CompanyINDUSTRY | 12 | Jun 29, 2020 | clinicaltrials |
| NCT01446159 | Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer | completed | Phase 2 | 188 | MedImmune LLCINDUSTRY | 11 | Jun 2, 2020 | clinicaltrials |
| NCT01792050 | Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer | completed | Phase 2 | 169 | NewLink Genetics CorporationINDUSTRY | 2 | May 28, 2020 | clinicaltrials |
| NCT02343406 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas(INTELLANCE-2) | completed | Phase 2 | 266 | AbbVieINDUSTRY | 21 | May 22, 2020 | clinicaltrials |
| NCT00806286 | Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 111 | Daiichi SankyoINDUSTRY | 4 | May 13, 2020 | clinicaltrials |
| NCT02333058 | Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | completed | Phase 2 | 70 | medac GmbHINDUSTRY | 6 | May 4, 2020 | clinicaltrials |
| NCT00784303 | Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology | completed | Phase 2 | 117 | Eisai Inc.INDUSTRY | 6 | Apr 22, 2020 | clinicaltrials |
| NCT00006229 | Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 774 | NCIC Clinical Trials GroupNETWORK | 14 | Apr 6, 2020 | clinicaltrials |
| NCT04029428 | Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression(POLNETS_PRRT) | unknown | Phase 2 | 150 | University of Warmia and MazuryOTHER | 1 | Apr 1, 2020 | clinicaltrials |
| NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | completed | Phase 2 | 60 | Grifols Therapeutics LLCINDUSTRY | 10 | Mar 30, 2020 | clinicaltrials |
| NCT03123055 | A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-22) | terminated | Phase 1 / Phase 2 | 28 | Rainier TherapeuticsINDUSTRY | 17 | Mar 18, 2020 | clinicaltrials |
| NCT02544633 | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | completed | Phase 2 | 68 | Mirati Therapeutics Inc.INDUSTRY | 9 | Mar 4, 2020 | clinicaltrials |
| NCT01546038 | A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 255 | PfizerINDUSTRY | 6 | Mar 3, 2020 | clinicaltrials |
| NCT00426764 | A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma | completed | Phase 2 | 131 | CelgeneINDUSTRY | 10 | Feb 11, 2020 | clinicaltrials |
| NCT01207388 | Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)(BLAST) | completed | Phase 2 | 116 | Amgen Research (Munich) GmbHINDUSTRY | 11 | Feb 10, 2020 | clinicaltrials |
| NCT00313170 | A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg(FINDER II) | completed | Phase 2 | 144 | AstraZenecaINDUSTRY | 8 | Jan 6, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 | clinicaltrials |
| NCT01984242 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma(IMmotion150) | completed | Phase 2 | 305 | Hoffmann-La RocheINDUSTRY | 9 | Dec 23, 2019 | clinicaltrials |
| NCT00263588 | Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer | completed | Phase 2 | 242 | Novartis PharmaceuticalsINDUSTRY | 17 | Dec 12, 2019 | clinicaltrials |
| NCT00989261 | Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)(ACE) | completed | Phase 2 | 333 | Daiichi SankyoINDUSTRY | 9 | Dec 11, 2019 | clinicaltrials |
| NCT00628251 | Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer(ICEBERG 3) | completed | Phase 2 | 97 | AstraZenecaINDUSTRY | 9 | Dec 5, 2019 | clinicaltrials |
| NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer(DARZALEX) | completed | Phase 1 / Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT00388960 | Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 99 | CelgeneINDUSTRY | 5 | Nov 19, 2019 | clinicaltrials |
| NCT00401843 | A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 307 | Janssen Research & Development, LLCINDUSTRY | 18 | Nov 19, 2019 | clinicaltrials |
| NCT03891472 | Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer | completed | Phase 2 | 40 | Medical University of SilesiaOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT00106431 | A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) | completed | Phase 2 | 102 | CelgeneINDUSTRY | 6 | Oct 30, 2019 | clinicaltrials |
| NCT00643565 | A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma. | completed | Phase 2 | 154 | Hoffmann-La RocheINDUSTRY | 14 | Oct 22, 2019 | clinicaltrials |
| NCT01602224 | A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) | completed | Phase 2 | 220 | Eli Lilly and CompanyINDUSTRY | 15 | Oct 8, 2019 | clinicaltrials |
| NCT00709995 | A Study for Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 17 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 30, 2019 | clinicaltrials |
| NCT01204710 | A Study of Olaratumab (IMC-3G3) in Prostate Cancer | completed | Phase 2 | 123 | Eli Lilly and CompanyINDUSTRY | 7 | Sep 20, 2019 | clinicaltrials |
| NCT01769391 | A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer | completed | Phase 2 | 167 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 20, 2019 | clinicaltrials |
| NCT00875667 | A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)(Sprint) | completed | Phase 2 | 254 | CelgeneINDUSTRY | 14 | Sep 16, 2019 | clinicaltrials |
| NCT01160744 | A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 280 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 13, 2019 | clinicaltrials |
| NCT01107444 | Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 180 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 11, 2019 | clinicaltrials |
| NCT01890746 | A Safety and Efficacy Study of Eltrombopag in Subjects With AML | completed | Phase 2 | 148 | Novartis PharmaceuticalsINDUSTRY | 10 | Sep 11, 2019 | clinicaltrials |
| NCT00274469 | A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer(FIRST) | completed | Phase 2 | 205 | AstraZenecaINDUSTRY | 9 | Sep 6, 2019 | clinicaltrials |
| NCT02768207 | A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma | completed | Phase 2 | 40 | Hoffmann-La RocheINDUSTRY | 2 | Aug 28, 2019 | clinicaltrials |
| NCT01901432 | A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera | completed | Phase 1 / Phase 2 | 48 | ItalfarmacoINDUSTRY | 5 | Jul 30, 2019 | clinicaltrials |
| NCT01646125 | An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | terminated | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 24, 2019 | clinicaltrials |
| NCT02046070 | Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | completed | Phase 2 | 148 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jul 17, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials